3 results
Approved WMOCompleted
see protocol summary
Approved WMORecruiting
Primary objectives:1) To determine whether concurrent ATII-antagonist treatment can prevent trastuzumab-related cardiotoxicity, defined as a decline in LVEF of more than 15% or a decrease to an absolute value <45%Secondary objectives:1) To…
Approved WMORecruiting
The primary objective of this study is to evaluate the effect of obicetrapib on LDL-C levels at Day 84. The secondary objectives of this study include the following: - To evaluate the effect of obicetrapib on fasting apolipoprotein B (ApoB), non-…